Additionally, Fabiani et al. [26] assessed uveitis flare rates in 37 patients with noninfectious uveitis who switched from various anti-TNF-α originators to their respective biosimilars, including Imraldi® (adalimumab biosimilar), Flixabi® (SB2, infliximab biosimilar, Samsung Bioepis, Incheon, Republic of Korea), Inflectra® (CT-P13, infliximab biosimilar, Pfizer Inc., New York, NY, USA), and Benepali® (SB4, etanercept biosimilar, Samsung Bioepis, Incheon, Republic of Korea). This evidence concerns the gene TNF and uveitis.